Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 2.59
ALIM's Cash to Debt is ranked higher than
69% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. ALIM: 2.59 )
ALIM' s 10-Year Cash to Debt Range
Min: 0.32   Max: 508.46
Current: 2.59

0.32
508.46
Equity to Asset -0.25
ALIM's Equity to Asset is ranked lower than
61% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. ALIM: -0.25 )
ALIM' s 10-Year Equity to Asset Range
Min: -0.25   Max: -0.25
Current: -0.25

F-Score: 3
Z-Score: -20.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1837.82
ALIM's Operating margin (%) is ranked lower than
60% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.34 vs. ALIM: -1837.82 )
ALIM' s 10-Year Operating margin (%) Range
Min: -1837.82   Max: -1837.82
Current: -1837.82

Net-margin (%) -2469.50
ALIM's Net-margin (%) is ranked lower than
60% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. ALIM: -2469.50 )
ALIM' s 10-Year Net-margin (%) Range
Min: -2469.5   Max: -2469.5
Current: -2469.5

ROA (%) -235.62
ALIM's ROA (%) is ranked lower than
61% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.95 vs. ALIM: -235.62 )
ALIM' s 10-Year ROA (%) Range
Min: -673.95   Max: -23.27
Current: -235.62

-673.95
-23.27
ROC (Joel Greenblatt) (%) -924.84
ALIM's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.63 vs. ALIM: -924.84 )
ALIM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19332.46   Max: -924.84
Current: -924.84

-19332.46
-924.84
EBITDA Growth (%) 13.30
ALIM's EBITDA Growth (%) is ranked higher than
79% of the 504 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.00 vs. ALIM: 13.30 )
ALIM' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 13.3
Current: 13.3

0
13.3
EPS Growth (%) 19.50
ALIM's EPS Growth (%) is ranked higher than
82% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. ALIM: 19.50 )
ALIM' s 10-Year EPS Growth (%) Range
Min: 0   Max: 19.5
Current: 19.5

0
19.5
» ALIM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ALIM Guru Trades in Q1 2013

Columbia Wanger 2,849,280 sh (-1.32%)
» More
Q2 2013

ALIM Guru Trades in Q2 2013

Columbia Wanger 2,849,280 sh (unchged)
» More
Q3 2013

ALIM Guru Trades in Q3 2013

Columbia Wanger 3,016,280 sh (+5.86%)
» More
Q4 2013

ALIM Guru Trades in Q4 2013

Columbia Wanger 3,016,280 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ALIM



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 106.40
ALIM's P/S is ranked lower than
90% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. ALIM: 106.40 )
ALIM' s 10-Year P/S Range
Min: 38.83   Max: 512
Current: 106.4

38.83
512
EV-to-EBIT 3.00
ALIM's EV-to-EBIT is ranked higher than
97% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. ALIM: 3.00 )
ALIM' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.90
ALIM's Price/Median PS Value is ranked higher than
79% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. ALIM: 0.90 )
ALIM' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 0.7
Current: 0.9

Forward Rate of Return (Yacktman) -82.32
ALIM's Forward Rate of Return (Yacktman) is ranked lower than
55% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. ALIM: -82.32 )
ALIM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -82.32

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:ASZ.Germany
Alimera Sciences, Inc., was incorporated in Delaware on June 4, 2003. It is a biopharmaceutical company that is engaged in the research, development, and commercialization of ophthalmic pharmaceuticals. The Company presently focuses on diseases affecting the back of the eye, or retina, which are well treated with current therapies. Its advanced product candidate is ILUVIEN, an intravitreal implant providing a therapeutic effect for up to 36 months in the treatment of vision impairment associated with DME by delivering sustained sub-microgram levels of FAc, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. ILUVIEN is implanted in the back of the patient's eye in a non-surgical procedure using an implantation device (the ILUVIEN applicator) employing a 25-gauge needle, which allows for a self-sealing wound. Intravitreal refers to the space inside the eye behind the lens that contains the jelly-like substance called vitreous. In September 2010, the company completed its FAME Study, two Phase 3 pivotal clinical trials on both ILUVIEN and a higher dose FAc intravitreal insert involving 956 patients in sites across the U.S., Canada, Europe and India to assess the efficacy and safety of ILUVIEN in the treatment of DME over a 36 month period. It owned or has licensed four U.S. utility patents, one U.S. design patent and five U.S. patent applications. The Company faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The research, testing, manufacturing and marketing of drug products are subject to extensive regulation by U.S. federal, state and local government authorities, including the FDA and similar entities in other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide